All Blog Posts Tagged 'PLX4032' (4)

Panel of Melanoma Mutations Valuable Tool for Hypothesis Generation and Testing - Opening the Door to New Treatment Possibilities

Researchers have developed a new genetic screening tool that will aid in the investigation of possible treatments for patients with melanoma and the unique genetic mutations that may accompany the disease, according to data presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held November 12-16, 2011 in San Francisco, CA, USA.

Heinz-Herbert Fiebig, M.D., Ph.D., associate professor of medical oncology at the…

Continue

Added by Peter Hofland, PhD on November 15, 2011 at 1:30pm — No Comments

Vemurafenib Improves Overall Survival in Advanced Melanoma

A randomized, international Phase III trial showed that vemurafenib (PLX4032/RO5185426, Roche/Plexxikon), which targets the V600E mutations in the BRAF gene, is the first drug to improve overall survival when compared to standard chemotherapy in patients with advanced melanoma.

It is also the first drug to improve progression-free survival (PFS) and… Continue

Added by Peter Hofland, PhD on June 5, 2011 at 11:30am — No Comments

Personalized Investigational Medicine Shows Survival Benefit in BRAF V600 Mutation-positive Metastatic Melanoma

The BRIM3 trial, a Phase III clinical study of RG7204 (also called RO5185426 or PLX4032), met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma. The drug candidate is under development by F. Hoffmann-La Roche Ltd and Plexxikon Inc. Study participants who received RG7204 lived longer… Continue

Added by Peter Hofland, PhD on January 19, 2011 at 11:30am — No Comments

Promising New Drugs for Melanoma Presented at International Melanoma Congress in Australia

Progress in the development of new targeted drug therapies addressing the alarming rise of deadly melanoma skin cancers and promising new clinical trial data have been presented during the 7th Annual Melanoma Research Congress and 4th Melanoma and Skin Cancer Centres Meeting in Sydney which was held earlier this month in Sydney, Australia

According to the… Continue

Added by Peter Hofland, PhD on November 8, 2010 at 7:00am — No Comments